Acute Agitation and Aggression Treatment Market Size
The global acute agitation and aggression treatment market was valued at USD 5.26 billion in 2025 and is estimated to reach USD 8.56 billion by 2033, growing at a CAGR of 8.8% during the forecast period from 2026 to 2033. The market is witnessing steady growth driven by the increasing prevalence of psychiatric disorders and the rising need for rapid and effective management of acute behavioral episodes.
Market growth is primarily fueled by the growing incidence of conditions such as schizophrenia, bipolar disorder, dementia, and substance abuse disorders, which are often associated with agitation and aggression. The increasing demand for fast-acting pharmacological treatments, including antipsychotics and benzodiazepines, is further accelerating market expansion. Additionally, the rising awareness of mental health, improved access to healthcare services, and supportive government initiatives are contributing to increased diagnosis and treatment rates.
Acute agitation and aggression treatments play a critical role in stabilizing patients and preventing harm to themselves and others in emergency and clinical settings. These treatments are widely used in hospitals, psychiatric facilities, and emergency care units. Continuous advancements in drug formulations, including intranasal and rapid-onset injectables, are improving treatment efficacy and patient compliance. With growing focus on mental health care, patient safety, and effective crisis management, the acute agitation and aggression treatment market is emerging as an essential segment within the global healthcare industry.
Acute Agitation and Aggression Treatment Market Scope
| Metrics | Details |
| CAGR | 8.8% |
| Segments Covered | By Drug Class, By Route of Administration, By End-Users, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Regions Analyzed | North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world. |
| Major Companies Covered | Abbott Laboratories, EKF Diagnostics Holdings plc, BioMérieux SA, Atlas Medical, Quidel Corporation, BIOSYNEX SA, Prestige Brands Holdings, Swiss Precision Diagnostics (SPD) GmbH, Piramal Enterprises, NG BIOTECH SAS, and among the major companies listed in the final report. |
To know more Download Sample
Acute Agitation and Aggression Treatment Market Dynamics
An increase in the incidence of dementia in the geriatric population continues supporting the market's growth during the forecast period
Dementia and depression are some of the most prevalent mental and neurological disorders. Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow and overpower a social stigma related to mental disorders treatment. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.
Moreover, increasing workplace stress is driving the growth of the global market. A major driving factor for acute agitation and aggression is increasing workplace stress. Workplace stress can have a lot of origins or come from a single event. It can affect employees as well as employers alike. According to the National Institute of Mental Health, in 2020, an estimated 52.9 million adults aged 18 or older than this in the United States with AMI. This number represented 21.0% of all U.S. adults. This prevalence of any mental illness was higher in females (25.8%) than males (15.8%). Young adults aged 18-25 years had the highest prevalence of AMI (30.6%) compared to adults aged 26-49 years (25.3%) and aged 50 and older (14.5%). Also, an increased level of stress was reported in the U.S. For instance, as per the American Institute of Stress (AIS), various studies demonstrated that job stress is a major reason for the stress among adults in the U.S., which has intensified in the last decade.
Acute Agitation and Aggression Treatment Market Segmentation
The anti-psychotics segment accounted for the highest share in global acute agitation and aggression treatment market
Dementia and depression are some of the most prevalent mental and neurological disorders. According to the World Health Organization, Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues, such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow or overcome a social stigma related to the treatment of mental disorders. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.
Based on the route of administration, the acute agitation and aggression treatment market has been bifurcated into oral, intramuscular, and other routes. The oral segment dominated the global acute agitation and aggression treatment market in the forecast period. In the acute agitation and aggression treatment market, the major route of administration is an oral treatment. Several drugs are offered by the key market players, taken orally to treat acute agitation and aggression. The lack of awareness of the intramuscular treatment solutions for acute agitation and aggression further contributes to the rise in the adoption of oral treatment solutions. The intramuscular administration route is generally preferred to the subcutaneous route, especially when larger drug solutions are needed. Moreover, a longer needle is required for the intramuscular route, limiting its adoption and supporting the growth of the oral route of administration to treat acute agitation and aggression.
Acute Agitation and Aggression Treatment Market Geographical Share
North America leads the global market throughout the forecast period
North America dominated the global acute agitation and aggression treatment market and is expected to retain its position during the forecast period. The US contributed the highest market share in the North American acute agitation and aggression treatment market. The well-developed healthcare infrastructure, including the established mental health institutions and mental health structure, supports its acute agitation and aggression treatment market. Moreover, key players such as Pfizer Inc., Janssen Biotech, Inc., and Eli Lilly and Company are further driving market growth in the region.
The Asia Pacific is estimated to grow at a considerable growth rate in the acute agitation and aggression treatment market during the forecast period. This growth can be attributed to the expansion of market players in the region, given the high investment by governments in the Asia Pacific in establishing informal healthcare infrastructure.
Recent Developments
February 2026: In North America, particularly the United States, the increasing prevalence of psychiatric disorders such as schizophrenia, bipolar disorder, and Alzheimer ’s-related agitation significantly accelerated demand for acute agitation and aggression treatments, supported by rising emergency care visits and expanding mental health services.
January 2026: In Europe, countries such as Germany, France, and the United Kingdom strengthened mental health policies and clinical intervention frameworks, driving adoption of rapid-acting pharmacological therapies and integrated behavioral treatment approaches.
December 2025: In Asia Pacific, especially China, India, and Japan, rising awareness of mental health conditions, improving healthcare infrastructure, and growing patient population positioned the region as a high-growth market for acute agitation and aggression treatment solutions.
November 2025: In the Middle East & Africa, increasing investments in healthcare infrastructure and gradual expansion of psychiatric care services supported steady adoption of treatment options, particularly in hospital and emergency care settings.
October 2025: Globally, rapid advancements in pharmacological treatments, including fast-acting antipsychotics and benzodiazepines, along with growing focus on non-pharmacological interventions, significantly improved patient management and treatment outcomes.
September 2025: Across global markets, increasing R&D activities and drug pipeline advancements, including novel therapies for Alzheimer’s-related agitation, accelerated innovation and highlighted strong unmet clinical needs in this segment.
The market is rapidly evolving toward fast-acting, patient-centric, and integrated treatment approaches, with strong growth driven by rising mental health burden, increasing emergency care demand, and continuous advancements in pharmacological and behavioral therapies, positioning acute agitation and aggression treatment as a critical component of modern psychiatric care systems.
Competitive Landscape
The acute agitation and aggression treatment market is highly competitive. The key acute agitation and aggression treatment players contributing to the global market's growth include Eli Lilly and Company, Janssen Biotech, Inc. (Johnson & Johnson), Ono Pharmaceutical Co., Ltd., Mylan NV, Impel Pharmaceuticals and Pfizer Inc. The major players are adopting new product launches and expansion strategies for global growth in the acute agitation and aggression treatment market. In July 2022, Impel Pharmaceuticals Announced First Patient Dosed in Phase 2a Evaluating INP105 especially to Treat Acute Agitation in Adolescents with Autism Spectrum Disorder. INP105 is specially developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) by using Impel's proprietary Precision Olfactory Delivery (POD) technology that delivers drugs to the upper nasal space. Results of this dose are expected in Q1 2023. Also, in April 2022, BioXcel Therapeutics Announced that they got FDA Approval for IGALMI (dexmedetomidine) Sublingual Film, which is used in Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults. This approval is generally based on data from two pivotal randomized, double-blinded, placebo-controlled, parallel-group Phase 3 trials evaluating dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.
The global acute agitation and aggression treatment market report would provide an access to approximately 61 market data tables, 52 figures and 170 pages.
